ASH 2018 | MAIA trial: addition of daratumumab to Rd in newly diagnosed transplant-ineligible MM
Thierry Facon, MD, Claude Huriez Hospital, Lille, France, presents the interim results of the Phase III MAIA trial (NCT02252172), which evaluated the addition of daratumumab to lenalidomide/dexamethasone (D-Rd) vs. Rd alone in transplant-ineligible newly diagnosed multiple myeloma (NDMM). The D-Rd regimen significantly reduced the risk of progression or death, with no new safety signals. Combined with the results of the ALCYONE study (D-VMP vs. VMP; NCT02195479), these data support the addition of daratumumab to the standard of care in transplant-ineligible NDMM. This video was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Get great new content delivered to your inboxSign up